Pulmonx Corporation (LUNG) vs Tiziana Life Sciences Ltd (TLSA)

A side-by-side comparison of Pulmonx Corporation and Tiziana Life Sciences Ltd across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — LUNG vs TLSA

growth of $100 · dividends reinvested · last 6y
LUNG -95.2% (-39.8%/yr)TLSA -68.8% (-17.6%/yr)TLSA compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$5$31
LUNG TLSA

LUNG vs TLSA: by the numbers

  • •LUNG is the larger company ($75M vs $71M market cap).
  • •Both run net losses; TLSA's is the smaller (0.00% vs -55.03% net margin).

Metrics side by side

Valuation

MetricLUNGTLSA
P/S ratio0.86N/A
P/B ratio1.921358.25

Profitability

MetricLUNGTLSA
Gross margin77.06%0.00%
Operating margin-52.96%0.00%
Net margin-55.03%0.00%
ROE-122.76%-35444.23%
ROIC-48.39%N/A

Growth (annualized)

MetricLUNGTLSA
Revenue CAGR (5Y)15.86%N/A
Total return CAGR (5Y)-45.30%-5.37%

Frequently asked

How have LUNG and TLSA total returns compared?
Over the past 5 years, LUNG delivered -45.30% and TLSA delivered -5.37% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.